about
1-, 3- and 8-substituted-9-deazaxanthines as potent and selective antagonists at the human A2B adenosine receptorDesign, synthesis, and structure-activity relationships of 1-,3-,8-, and 9-substituted-9-deazaxanthines at the human A2B adenosine receptor5-amino-6-phenyl-1,6-dihydropyridazin-3(2H)-onePyridazines. Part 28: 5-alkylidene-6-phenyl-3(2H)-pyridazinones, a new family of platelet aggregation inhibitors.Design, synthesis, and structure-activity relationships of a novel series of 5-alkylidenepyridazin-3(2H)-ones with a non-cAMP-based antiplatelet activity.Straightforward three-component palladium-catalysed synthesis of pyridazin-3(2H)-one libraries.Straightforward entry to libraries of diversely substituted azinones by a consecutive aza-Michael/palladium-catalyzed functionalization strategy.Divergent solution-phase synthesis of diarylpyrimidine libraries as selective A3 adenosine receptor antagonists.Three-component assembly of structurally diverse 2-aminopyrimidine-5-carbonitriles.Ugi-based approaches to quinoxaline libraries.Structure-based design of new KSP-Eg5 inhibitors assisted by a targeted multicomponent reaction.Computer-aided design of GPCR ligands.Personality traits in patients with cluster headache: a comparison with migraine patients.Structure-Based Rational Design of Adenosine Receptor Ligands.Pyrazin-2(1H)-ones as a novel class of selective A3 adenosine receptor antagonists.Pyrimidine derivatives as potent and selective A3 adenosine receptor antagonists.Discovery of 3,4-Dihydropyrimidin-2(1H)-ones As a Novel Class of Potent and Selective A2B Adenosine Receptor Antagonists.Synthesis, adenosine receptor binding and 3D-QSAR of 4-substituted 2-(2'-furyl)-1,2,4-triazolo[1,5-a]quinoxalines.Parallel regulation by olanzapine of the patterns of expression of 5-HT2A and D3 receptors in rat central nervous system and blood cells.8-Substituted-9-deazaxanthines as adenosine receptor ligands: design, synthesis and structure-affinity relationships at A2B.Development of Fluorescent Probes that Target Serotonin 5-HT2B Receptors.Synthesis and Characterization of a New Bivalent Ligand Combining Caffeine and Docosahexaenoic Acid.Pyridazines. Part XXIX: synthesis and platelet aggregation inhibition activity of 5-substituted-6-phenyl-3(2H)-pyridazinones. Novel aspects of their biological actions.1,5-dimethyl-6H-pyridazino[4,5-b]carbazole, a 3-aza bioisoster of the antitumor alkaloid olivacine.Pyridazine derivatives 32: Stille-based approaches in the synthesis of 5-substituted-6-phenyl-3(2H)-pyridazinones.Multicomponent assembly of diverse pyrazin-2(1H)-one chemotypes.Synthesis of 1-substituted-6-methyluracils.Pyridazines. Part 36: Synthesis and antiplatelet activity of 5-substituted-6-phenyl-3(2H)-pyridazinones.Selective and potent adenosine A3 receptor antagonists by methoxyaryl substitution on the N-(2,6-diarylpyrimidin-4-yl)acetamide scaffold.Synthetic applications of polystyrene-supported 1,1,3,3-tetramethylguanidine.Click chemistry approach to assembly proline mimetic libraries containing 1,4-substituted 1,2,3-triazoles.Design, synthesis, and biological evaluation of glycine-based molecular tongs as inhibitors of Abeta1-40 aggregation in vitro.Pyridazines part 41: synthesis, antiplatelet activity and SAR of 2,4,6-substituted 5-(3-oxo-3-phenylprop-1-en-1-yl)- or 5-(3-phenylprop-2-enoyl)pyridazin-3(2H)-ones.2-Substituted 4-, 5-, and 6-[(1E)-3-oxo-3-phenylprop-1-en-1-yl]pyridazin-3(2H)-ones and 2-substituted 4,5-bis[(1E)-3-oxo-3-phenylprop-1-en-1-yl]pyridazin-3(2H)-ones as potent platelet aggregation inhibitors: design, synthesis, and SAR studies.Computer-aided design of multi-target ligands at A1R, A2AR and PDE10A, key proteins in neurodegenerative diseases.Structural Mapping of Adenosine Receptor Mutations: Ligand Binding and Signaling Mechanisms.Structure-Based Design of Potent and Selective Ligands at the Four Adenosine Receptors.Effect of Nitrogen Atom Substitution in A3 Adenosine Receptor Binding: N-(4,6-Diarylpyridin-2-yl)acetamides as Potent and Selective Antagonists.Multicomponent Assembly of the Kinesin Spindle Protein Inhibitor CPUYJ039 and Analogues as Antimitotic Agents.Enantiospecific Recognition at the A2B Adenosine Receptor by Alkyl 2-Cyanoimino-4-substituted-6-methyl-1,2,3,4-tetrahydropyrimidine-5-carboxylates.
P50
Q28266208-D811C32A-074A-4C5D-8A0F-767888BEB929Q28289798-395ED48C-FB93-40B5-A593-B6B6AE2CD3D0Q28377457-99A32698-B23C-45B3-9CA7-5782D6BCDC30Q30695570-A80D66A1-B001-4A63-9393-2A240BA0ADADQ31137381-3BD8141E-20AB-4458-9DDA-946D495A76A3Q33232959-71085A21-FD96-40E1-B748-F9BC4A763B59Q33242435-47774946-20D6-4A97-8B36-AEF6F611BF6BQ33453741-35B1D95E-A026-4164-AFD7-394C28D23566Q34734406-92CF0C1F-0720-4D3E-B0D4-8A496812C593Q35163549-1308D42D-8182-4098-A584-83237AE3223BQ35190903-DB40E1A4-BD09-45C0-A6D4-023BC35F9A8EQ35538917-D9EF2035-5351-436F-A5A9-72748762210FQ36685891-3A18830E-9487-4FE5-AD3C-495448F96BF8Q38905802-764917FB-1FAA-4BB1-BFF6-642DB84D203EQ38979023-971BED62-4F49-45C3-968C-12FA8810D4D4Q39615457-B26382B5-646E-4E81-8704-BAF63A8A2068Q39775269-D03E44F5-D6F7-4445-8F65-AE4EDF9FD188Q40127036-A470F3B1-1658-4713-82F7-33DF8D96CB0DQ40298384-F184EAE7-D014-4BA2-A3E0-BAE8133CFAECQ40508359-F3704C9A-09E8-4EE2-943D-96CD8397CA40Q41538383-9C6D7FEB-397F-4938-AA32-56FBF1DDCB81Q42506560-1878D0C3-40B1-44FE-8EFD-C636C5F4C60EQ44057875-CB20569F-6342-454B-BDE0-9227A9D24249Q44207799-FC92E82C-F263-46AC-8543-46BD31C18455Q44388812-8D5ADDED-4830-48D1-9995-9BB3331F2DCFQ44492319-726B6633-DD3A-45AE-BE48-2FB88A66345BQ44570785-186AFD67-06D8-4F78-BD51-A5C412A87BE8Q44708014-6363CB35-2005-42AA-AC92-CDAFD3B33CA9Q45783242-C8D148CB-54E2-4817-986F-E711A05CDCDDQ46201738-2384411C-F0BF-4EBC-9B80-B3CA70DF3F53Q46620710-7B17FA6A-D840-488B-809A-B84DD5FC5421Q46649386-7BE8910A-DC8C-4954-AAA4-8EC35FEE3039Q46806144-54882103-9A83-4471-8D92-6F96858EB010Q46870732-EA84CB31-73D3-4E2C-8820-9F9C1F240111Q47242194-9A6133AE-B63C-4296-8AC3-C4474C325119Q47333337-AA5DF65F-6DDC-4E11-BF97-E8B5C0EDE65FQ47417018-4F915BB2-18A5-44E0-96F3-9CC184F0879BQ47935638-5741C180-B263-4CB8-9BF4-F05E804238F9Q48298446-65B0ADBC-9581-41C4-94F8-048B37119DA0Q48336780-D079A26F-0518-4174-84F8-EE01B34E0EF0
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Eddy Sotelo
@ast
Eddy Sotelo
@en
Eddy Sotelo
@es
Eddy Sotelo
@nl
Eddy Sotelo
@sl
type
label
Eddy Sotelo
@ast
Eddy Sotelo
@en
Eddy Sotelo
@es
Eddy Sotelo
@nl
Eddy Sotelo
@sl
prefLabel
Eddy Sotelo
@ast
Eddy Sotelo
@en
Eddy Sotelo
@es
Eddy Sotelo
@nl
Eddy Sotelo
@sl
P1053
C-3351-2012
P106
P21
P2798
P31
P3829
P496
0000-0001-5571-2812